NPI-001 Enters Phase 3 Trial for Usher Syndrome Vision
The two-year study tests if the oral tablet can slow photoreceptor loss in adults with retinitis pigmentosa.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to put patient needs above their own clinical research goals?
Nacuity Pharmaceuticals has dosed the first patient in a Phase 3 clinical trial evaluating NPI-001 for retinitis pigmentosa linked to Usher syndrome. The late-stage study is now active across sites in the United States and Australia.
Why it matters
Usher syndrome lacks effective standard treatments for the associated vision loss, making this trial a critical milestone in determining if NPI-001 can successfully mitigate photoreceptor decline. The study serves as a pivotal step toward regulatory approval for the drug.
The study is a randomized, double-masked trial involving up to 80 adult participants. Subjects are monitored over a 24-month period across nine in-clinic visits to determine the drug's impact on disease progression.
The players
Nacuity Pharmaceuticals
A clinical-stage biotechnology company headquartered in Fort Worth, Texas, focused on developing therapies for inherited retinal degenerative diseases.
The details
The trial evaluates NPI-001, a tablet administered orally twice daily by participants. NPI-001 is designed to preserve sight by reducing photoreceptor loss, the specialized sensory cells in the retina that convert light into nerve signals. By slowing this degenerative process, the drug aims to preserve visual function in patients with Usher syndrome-associated retinitis pigmentosa.
Timeline
October 28, 2026: First patient dosed in the Phase 3 study.
The clinical trial duration spans approximately 24 months.
The Tech Race
The study follows a development path enabled by the FDA Orphan Drug designation, which provides seven years of market exclusivity upon approval. This trial accelerates the competition to bring the first effective pharmacological treatment for Usher syndrome-related vision loss to market.
Patients currently enrolling in the trial will self-administer the study medication twice daily over the two-year period. Potential participants can access enrollment information through the study's official portal.
The takeaway
NPI-001 is currently operating under FDA Fast Track and Breakthrough Therapy designations to speed development. Watch for future interim analysis reports from the 24-month data collection period to gauge the drug's therapeutic potential.
Further reading
For more on the latest research and clinical progress, visit the Biotech section.
More information
Review the full study details at the study enrollment and information portal.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical companies to put patient needs above their own clinical research goals?
